



## **PSIOXUS THERAPEUTICS STRENGTHENS TEAM WITH TWO APPOINTMENTS**

### ***Addition of Non-Executive Board Director and Expanded Scientific Advisory Board Position Development Stage Biotech for Growth and Commercialisation***

**LONDON – 17 January, 2012 – [PsiOxus Therapeutics, Ltd.](#)** (PsiOxus) has appointed Dr Paolo Paoletti, President of GlaxoSmithKline's (GSK) Global Oncology Business as a non-executive board director, and added Dr Terry Hermiston, Vice President of Biologics Research at Bayer Healthcare Pharmaceuticals, to its Scientific Advisory Board.

Dr Paoletti brings invaluable expertise in the discovery, development and commercialisation of new oncology products to the Board of Psioxus. As the first President of GSK's Global Oncology Business, Dr Paoletti has P&L accountability for the overall Oncology Business within GSK. In his role, Dr Paoletti champions an organization of more than 800 professionals around the world dedicated to fighting the causes and impacts of cancer. As the leader of the newly formed business unit, Dr Paoletti oversees all the activities within GSK Oncology spanning from early drug discovery through clinical development, as well as, product positioning, launch and life cycle management. Under Dr Paoletti's leadership, GSK Oncology has achieved an almost unprecedented level of success in bringing forth important advances to cancer care. Previously, he was Vice President Oncology at Eli-Lilly.

Dr Hermiston will advise Psioxus on the development of ColoAd1 and the pipeline of follow-on viral therapeutics and vaccines. Dr Hermiston is the inventor of the ColoAd1 oncolytic virus, which Psioxus Therapeutics will take into a phase I clinical trial in 2012. Dr Hermiston brings invaluable expertise in the discovery and development of novel biologics in general and oncolytic viruses in particular. Before joining Bayer (previously Berlex), Dr Hermiston was Associate Director of Oncolytic Virus Research at Onyx Pharmaceuticals. He is broadly published in the field of viral therapeutics and is the author of nine granted patents within the field. Dr Hermiston also currently serves as the Site Head of the Bayer Innovation Center in San Francisco.

"I am delighted to welcome these two outstanding individuals to Psioxus Therapeutics, each of them bring such impressive and relevant track records to our programs," said Dr John Beadle, CEO of PsiOxus. "Dr Hermiston's specific expertise and knowledge of ColoAd1 and oncolytic viruses will be invaluable to our scientific programs whilst Dr Paoletti's experience in the global development and commercialisation of novel cancer therapies will be critical in effectively and efficiently taking these programs to patients and ultimately to market. These appointments are a mark of our ambition for these programs."

For more information about PsiOxus Therapeutics, please contact:

PsiOxus Therapeutics  
Dr John Beadle, Chief Executive Officer

Tel +44 (0) 7810 770 310  
John.beadle@psioxus.com

US Media Enquiries: Erik Clausen at Chempetitive

Tel +1 781-608-7091  
PsiOxus@chempetitive.com

UK Media Enquiries: Tony Stephenson at Chempetitive

Tel +44 (0) 20 3159 4145  
tstephenson@chempetitive.com

Or visit [www.PsiOxus.com](http://www.PsiOxus.com)

### **About PsiOxusTherapeutics, Ltd.**

**PsiOxus Therapeutics** is a development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. The Company's lead candidate is **MT-102**, a dual action Anabolic Catabolic Transforming Agent (ACTA) in phase II clinical development for the treatment of cachexia and sarcopenia. **ColoAd1**, an oncolytic virus for the systemic treatment of metastatic cancer, has demonstrated optimal anti-cancer properties in late pre-clinical development. The Company is also developing treatments based upon the research phase vaccine platform **PolySTAR**, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform **PolyMAP**, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.

###